Fresh mango instead of table sugar at breakfast: effects on blood sugar, insulin, and blood vessels
Effects of Fresh Mango as a Sugar Substitute Within High and Low Glycemic Breakfasts on Postprandial Glucose and Insulin
This test will see if replacing table sugar with fresh mango in high- and low-glycemic breakfasts lowers post-meal blood sugar and insulin and improves blood vessel responses in healthy adults aged 18–45.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Sponsor | Ball State University Academic / other |
| Locations | 1 site (Muncie, Indiana) |
| Trial ID | NCT07045051 on ClinicalTrials.gov |
What this trial studies
Researchers will enroll healthy adults (BMI 18.5–35 kg/m2) for a randomized crossover protocol with four breakfast visits. Each visit participants will eat one of four matched meals (cornflakes + milk or steel-cut oats + water, each sweetened with either fresh mango or sucrose) while blood samples and brachial artery flow-mediated dilation are measured at scheduled times over three hours. Sugar content and total energy are closely matched between mango- and sucrose-sweetened meals to isolate the effect of mango components. Participants will also complete acceptability and satiety surveys after each meal.
Who should consider this trial
Good fit: Healthy adults aged 18–45 with BMI between 18.5 and 35 kg/m2 who are not pregnant or postmenopausal, do not have cardiovascular or cardiometabolic disease, do not regularly use certain medications (like glucose- or lipid-lowering drugs), and can consume mango, wheat/gluten, and milk are ideal candidates.
Not a fit: People with type 2 diabetes, cardiovascular disease, chronic inflammatory conditions, those outside the age or BMI range, pregnant or postmenopausal women, tobacco or illicit drug users, or those taking glucose- or lipid-lowering medications are unlikely to qualify or benefit from the findings.
Why it matters
Potential benefit: If successful, replacing sucrose with fresh mango at breakfast could reduce post-meal glucose and insulin spikes and support better short-term vascular responses.
How similar studies have performed: Prior small studies suggest mango can blunt postprandial glucose responses, but testing mango as a direct substitute for sucrose within larger, realistic mixed meals has been limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 - 45 years. * Body mass index between 18.5-35.0 kg/m2 * Not pregnant (females only) * Not postmenopausal (females only). * Not been diagnosed with cardiovascular disease. * Not been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes) * Not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease). * Does not regularly take anti-inflammatory drugs (more than 2x week). * Does not use glucose-lowering drugs (e.g., metformin) * Does not use lipid-lowering drugs (e.g., statins) * Does not use tobacco products or any illicit drugs. * Does not have a pacemaker. * Can consume mango, wheat, gluten, and milk. * Can stay in a supine position in the dark for at least ten minutes. Exclusion Criteria: * Not between the ages of 18-45 * Body mass index \< 18.5 kg/m2 or \>35.0 kg/m2 * Pregnant (females only) * Postmenopausal status (females only). * Been diagnosed with cardiovascular disease. * Been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes) * Been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease). * Regularly take anti-inflammatory drugs (more than 2x week). * Uses glucose-lowering drugs (e.g., metformin) * Uses lipid-lowering drugs (e.g., statins) * Uses tobacco products or any illicit drugs. * Have a pacemaker. * Allergic to mango, wheat, gluten, and/or milk. * Unable to lay in supine position in the dark for at least ten minutes.
Where this trial is running
Muncie, Indiana
- Health Professions Building, Ball State University — Muncie, Indiana, United States (Recruiting)
Study contacts
- Principal investigator: Bryant Keirns, PhD — Ball State University
- Study coordinator: Bryant Keirns, PhD
- Email: bryant.keirns@bsu.edu
- Phone: 765-285-8356
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.